ISSN: 2161-0681

Jornal de Patologia Clínica e Experimental

Acesso livre

Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Indexado em
  • Índice Copérnico
  • Google Scholar
  • Sherpa Romeu
  • Abra o portão J
  • Genâmica JournalSeek
  • JornalTOCs
  • Diretório de Periódicos de Ulrich
  • RefSeek
  • Universidade Hamdard
  • EBSCO AZ
  • OCLC – WorldCat
  • Publons
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Euro Pub
  • ICMJE
Compartilhe esta página

Abstrato

Comparison of Original and Internal Pathology Reports Referred for UrothelialCarcinoma to Determine Rate of Discrepancies and the Impact on Treatment Decisions

Luisa Cioci, La Mont Barlow, Edan Shapiro, Jennifer Ahn, Mitchell Benson, Guarionex J De Castro and James Mc Kiernan

Objective: The purpose of the current study is to perform a standardized comparison of original and internal repeat pathology reviews of identical bladder specimens to identify discrepancies and characterize the impact of repeat review on treatment decisions as well as identify patients most likely to benefit from this practice.

Materials/Methods: Ninety-one patients with an outside diagnosis of urothelial cancer of the bladder were referred to our institution for repeat review of 91 bladder resection specimens and biopsies.

A discrepancy in either the presence or absence of muscularis propria and presence of invasive disease in the muscularis propria was deemed a “treatment-altering” characteristic, while presence of carcinoma in situ, lymphovascular invasion, or micropapillary features was deemed a “clinically-significant” characteristic.

Results: After repeat review at our institution, 29.7% (27) specimens had treatment altering discrepancies, and 61.5% (56) specimens had at least one clinically-significant discrepancy.

Conclusion: Repeat review of referred bladder specimens frequently impacts treatment decisions in patients with urothelial carcinoma.